SeaStar Medical has hired Dr. Kevin Chung as chief medical officer of the medtech developer starting July 1.
Denver-based SeaStar is developing a platform therapy focused on hyperinflammation of vital organs. The company’s Selective Cytopheretic Device was designated as a breakthrough device by the FDA earlier this year.
SeaStar is set to go public in the third quarter of 2022 through a combination with special purpose acquisition company (SPAC) LMF Acquisition Opportunities (Nasdaq: LMAO).